For example, de novo MYC and EGFR gain/amp in liver and distant LN (#16) metastasis were observed in GCM10; as the efficacy of targeting each of MYC and EGFR has been reported [59–61], therefore, the strategy targeting both MYC and EGFR simutaneously focusing on the metastatic tumors might be a potential treatment option for the patient. This evidence concerns the gene EGFR and metastatic neoplasm.